Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

System for determining prognosis of hepatitis B related liver cancer by using TIGIT and TIM-3 on NK cell

A technology of TIM-3 and NK cells, applied in instruments, biomaterial analysis, measuring devices, etc., can solve the problems of lack of reliable biomarkers, and achieve the effect of convenient method and good adaptability of patients

Active Publication Date: 2021-08-17
BEIJING DITAN HOSPITAL CAPITAL MEDICAL UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

As for the monitoring of disease progression in patients with hepatitis B-related liver cancer, there is still a lack of reliable and appropriate biomarkers and related means and methods in this field.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • System for determining prognosis of hepatitis B related liver cancer by using TIGIT and TIM-3 on NK cell
  • System for determining prognosis of hepatitis B related liver cancer by using TIGIT and TIM-3 on NK cell
  • System for determining prognosis of hepatitis B related liver cancer by using TIGIT and TIM-3 on NK cell

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0053] Example 1 TIGIT for patients with hepatitis B-related liver cancer + TIM-3 + Increased expression of NK cells

[0054] To evaluate the expression levels of TIGIT and TIM-3, we analyzed the expression levels of TIGIT and TIM-3 in normal subjects, patients with chronic hepatitis B, patients with hepatitis B cirrhosis, and patients with hepatitis B-related liver cancer by flow cytometry.

[0055] First, we found that the proportion of total NK cells in patients with hepatitis B-related liver cancer was significantly lower than that of normal people and patients with chronic hepatitis B (Pfigure 1 a, 1b). Subsequently, we compared the proportion changes of TIGIT and TIM-3 in total NK cells and each subpopulation in normal subjects, patients with chronic hepatitis B, patients with hepatitis B cirrhosis, and patients with hepatitis B-related liver cancer. TIGIT in patients with hepatitis B-related liver cancer compared with the proportion of total NK cells in normal peopl...

Embodiment 2

[0056] Example 2 TIGIT + TIM-3 + High expression of NK cells is associated with progression in patients with hepatitis B-related liver cancer

[0057] To discuss TIGIT + TIM-3 + The relationship between NK cells and the clinical outcome of patients with hepatitis B-related liver cancer, we studied 133 patients with hepatitis B-related liver cancer. According to whether progress occurred or not, it was divided into progress group and non-progression group. Compare TIGIT + NK cells, TIM-3 + NK cells and TIGIT + TIM-3 + The proportion of NK cells in the two groups. We found that TIGIT + TIM-3 + The proportion of NK cells was significantly higher than that of the non-progressive group (P figure 2 d, 2e). According to TIGIT + TIM-3 + NK cell ratio to TIGIT + TIM-3 +The median (20.5%) of NK cell proportion was the cut-off value. We divided 133 patients with hepatitis B-related liver cancer into two groups: TIGIT + TIM-3 + High expression group (>20.5%) and TIGIT...

Embodiment 3

[0061] Example 3 TIGIT + TIM-3 + High expression of NK cells is associated with poor prognosis in hepatitis B-related liver cancer

[0062] To further determine the effect of tumor progression on TIGIT + TIM-3 + For the effect of co-expression, we used survival curves to compare the two groups in clinical subgroups (TIGIT + TIM-3 + High expression group and TIGIT + TIM-3 + low expression group) progression-free survival time. In the total population of HBV-related HCC, we found that TIGIT + TIM-3 + The progression-free survival rate of the high expression group was lower than that of TIGIT + TIM-3 + low expression group ( image 3 ; HR=2.05, 95% CI 1.24-3.04, P=0.005).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of TIGIT and TIM-3 as biomarkers in judging prognosis of hepatitis B related liver cancer patients. The TIGIT and the TIM-3 are TIGIT and TIM-3 on NK cells of the patient, and expression of the TIGIT and the TIM-3 on the NK cells can be used for assisting in predicting disease progression and outcome of the hepatitis B related liver cancer patient. In addition, the invention provides a new therapeutic target for patients, and provides a new thought for future immunotherapy of hepatitis B related liver cancer.

Description

technical field [0001] The invention belongs to the field of liver cancer diagnosis, and in particular, the invention relates to a biomarker for the progression of hepatitis B-related liver cancer and its application in the prognosis of hepatitis B-related liver cancer. Background technique [0002] Liver cancer is a common malignant tumor. According to the 2018 global cancer statistics, the death rate of liver cancer ranks fourth among cancers in the world. Hepatitis B virus infection is the main cause of liver cancer, and the high morbidity and mortality of Hepatitis BVirus Related Hepatocellular Carcinoma (HBV-HCC) has been the focus of research in this field. [0003] Biomarkers that can reflect the malignant biological behavior of tumor cells to a certain extent have been widely used in the early detection or diagnosis, progress monitoring, and prognosis evaluation of tumors or cancers, and can at least be used as an auxiliary evaluation method for clinicians and Patie...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/574
CPCG01N33/57438G01N33/57488G01N33/56972G01N2333/70503
Inventor 杨志云于莉华杜娟刘晓利江宇泳
Owner BEIJING DITAN HOSPITAL CAPITAL MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com